India's Mankind Pharma climbs on strong Q4 profit

Mankind Pharma

20/05/2026 04:55

** Shares of Mankind Pharma MNKI.NS rise 2.9% to 2,565 rupees

** Drugmaker reports 30.4% Y/Y profit growth in Q4 led by strong demand for its chronic therapies

** Rev from ops up 12% Y/Y

** Motilal Oswal says MNKI's profit and EBITDA beat its expectations on strength in its domestic business

** Avg rating of 17 analysts on MNKI at "buy"; median PT is 2,500 rupees - data compiled by LSEG

** YTD, stock up 16.8%

(Reporting by Kashish Tandon in Bengaluru)

((Kashish.tandon@thomsonreuters.com))